To explore whether the key transcription factors identified in the two network analyses, Egr1, Klf6, and Klf4, or other regulatory genes from the GRNs may serve as candidate targets for follow-up preclinical pharmacological inhibition studies to reverse or alleviate gender-associated pathological alterations in AD, we complemented the gene regulatory network analysis by further network perturbation analyses (see following section). The gene discussed is KLF4; the disease is Alzheimer disease.